Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVAIR DISKUS 100/50 vs ACLOVATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Long-term maintenance treatment of asthma in patients aged 4 years and older,Maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis,Off-label: Treatment of COPD exacerbations
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Fluticasone propionate undergoes extensive first-pass metabolism via cytochrome P450 3A4 (CYP3A4) to an inactive carboxylic acid metabolite. Salmeterol is metabolized primarily by CYP3A4 to alpha-hydroxysalmeterol.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Fluticasone propionate: approximately 90% bound to plasma proteins (primarily albumin). Salmeterol: approximately 96% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Fluticasone propionate: Vd approximately 4.2 L/kg (range 3-6 L/kg), indicating extensive tissue distribution. Salmeterol: Vd approximately 7 L/kg (range 5-10 L/kg), indicating extensive tissue distribution.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Fluticasone propionate: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 18% (range 15-21%), due to lung deposition and low oral bioavailability (<1%). Salmeterol: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 25% (range 20-30%), due to lung deposition; oral bioavailability is negligible.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
No dose adjustment required. Topical use with minimal systemic absorption.
Child-Pugh Class A: No adjustment. Child-Pugh Class B and C: Use with caution; consider reduced dose due to increased systemic exposure; monitor for adverse effects.
No dose adjustment required. Topical use with minimal systemic absorption.
Not recommended for children under 12 years. For adolescents 12 years and older, same as adult dosing: 1 inhalation twice daily.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
No specific dose adjustment; use lowest effective dose; monitor for systemic corticosteroid effects and cardiovascular events due to salmeterol.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Therefore, ADVAIR DISKUS 100/50 should only be used for asthma in patients not adequately controlled on a long-term asthma control medication (e.g., inhaled corticosteroid) or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
No FDA black box warning.
Increased risk of asthma-related death with LABA use,Cardiovascular effects (e.g., increased blood pressure, tachycardia, arrhythmias),Paradoxical bronchospasm,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Hypercorticism and adrenal suppression with high doses or prolonged use,Reduced bone mineral density with long-term use,Pneumonia risk in COPD patients,Ketoacidosis in patients with diabetes
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures,Hypersensitivity to fluticasone propionate, salmeterol, or any excipient,Severe hypersensitivity to milk proteins (due to lactose content)
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
No specific food interactions; avoid grapefruit juice as it may increase fluticasone systemic absorption. Take with or without food.
No known food interactions with topical Aclovate.
Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fetal weight) at doses ≥30 mcg/kg SC; salmeterol caused delayed ossification and reduced survival at doses ≥1.4 mg/kg PO. First trimester: No data for ADVAIR; avoid unless benefit outweighs risk. Second/third trimester: Use only if clearly needed; monitor fetal growth and consider risk of maternal asthma exacerbation.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
Fluticasone and salmeterol are excreted in breast milk in animals; unknown in humans. M/P ratio not determined. Consider developmental benefits of breastfeeding vs. potential for drug-induced adverse effects. Use caution if benefit to mother outweighs infant risk. For asthma, inhaled doses likely produce minimal systemic exposure, but monitor infant for respiratory symptoms or heart rate changes.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
No specific dose adjustments are recommended for ADVAIR DISKUS 100/50 during pregnancy. However, pregnancy may alter pharmacokinetics: increased clearance of fluticasone and salmeterol due to elevated blood volume and renal blood flow. Monitor asthma control closely; if deterioration occurs, consider increasing dose or adding other controller therapy. Do not exceed maximum recommended dose (500/50 twice daily).
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg/salmeterol 50 mcg) is a combination inhaler for maintenance therapy of asthma or COPD; not for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Monitor for increased blood pressure, tachycardia, and hypokalemia due to salmeterol. Do not use as monotherapy in asthma without inhaled corticosteroid; salmeterol increases risk of asthma-related death when used alone. Diskus device delivers medication via a breath-activated dry powder; ensure patient breaths in rapidly and deeply.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
Use exactly as prescribed; do not use more puffs than directed.,Rinse mouth with water after each use (do not swallow) to prevent thrush.,Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available.,If you miss a dose, skip it; do not double the dose.,Call your doctor if symptoms worsen or you need more rescue inhaler than usual.,Store diskus at room temperature away from moisture and heat; keep closed when not in use.,Do not stop taking this medicine without consulting your doctor.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVAIR DISKUS 100/50 vs ACLOVATE, answered by our medical review team.
ADVAIR DISKUS 100/50 is a Corticosteroid/LABA Combination that works by Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.. ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVAIR DISKUS 100/50 and ACLOVATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVAIR DISKUS 100/50 is: One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.. The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVAIR DISKUS 100/50 and ACLOVATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVAIR DISKUS 100/50 is classified as Category C. Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fe. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.